Oasmia Leveraging Platform, Advancing Veterinary Medicines
Oasmia Pharmaceuticals (NASDAQ: OASM) is firing on all cylinders. Earlier this week, the company announced positive overall survival (OS) data from its Phase 3 clinical study with Paclical/Apealea® for the treatment of ovarian cancer. After completing six treatment cycles, patients on Paclical/Apealea® plus carboplatin had a median overall survival of 25.7 months compared to 24.8 months…